BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Uijen MJM, Derks YHW, Merkx RIJ, Schilham MGM, Roosen J, Privé BM, van Lith SAM, van Herpen CML, Gotthardt M, Heskamp S, van Gemert WAM, Nagarajah J. PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports. Eur J Nucl Med Mol Imaging 2021. [PMID: 34120192 DOI: 10.1007/s00259-021-05433-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Brunello S, Salvarese N, Carpanese D, Gobbi C, Melendez-Alafort L, Bolzati C. A Review on the Current State and Future Perspectives of [99mTc]Tc-Housed PSMA-i in Prostate Cancer. Molecules 2022;27:2617. [PMID: 35565970 DOI: 10.3390/molecules27092617] [Reference Citation Analysis]
2 Urso L, Castello A, Rocca GC, Lancia F, Panareo S, Cittanti C, Uccelli L, Florimonte L, Castellani M, Ippolito C, Frassoldati A, Bartolomei M. Role of PSMA-ligands imaging in Renal Cell Carcinoma management: current status and future perspectives. J Cancer Res Clin Oncol 2022. [PMID: 35217902 DOI: 10.1007/s00432-022-03958-7] [Reference Citation Analysis]
3 Te Beek ET, Burggraaf J, Teunissen JJM, Vriens D. Clinical Pharmacology of Radiotheranostics in Oncology. Clin Pharmacol Ther 2022. [PMID: 35373336 DOI: 10.1002/cpt.2598] [Reference Citation Analysis]
4 van der Heide CD, Dalm SU. Radionuclide imaging and therapy directed towards the tumor microenvironment: a multi-cancer approach for personalized medicine. Eur J Nucl Med Mol Imaging 2022. [PMID: 35788730 DOI: 10.1007/s00259-022-05870-1] [Reference Citation Analysis]
5 Michalski K, Jilg CA, Engelhardt M, Meyer PT, Ruf J. Diffuse Bone Marrow Involvement of Multiple Myeloma on [18F]PSMA-1007 PET/CT: Is There a Theranostic Potential? Clin Nucl Med 2022. [PMID: 35619194 DOI: 10.1097/RLU.0000000000004286] [Reference Citation Analysis]
6 Gühne F, Seifert P, Theis B, Steinert M, Freesmeyer M, Drescher R. PSMA-PET/CT in Patients with Recurrent Clear Cell Renal Cell Carcinoma: Histopathological Correlations of Imaging Findings. Diagnostics (Basel) 2021;11:1142. [PMID: 34201583 DOI: 10.3390/diagnostics11071142] [Reference Citation Analysis]
7 Moon JB, Yoo SW, Lee C, Kim DY, Pyo A, Kwon SY. Multimodal Imaging-Based Potential Visualization of the Tumor Microenvironment in Bone Metastasis. Cells 2021;10:2877. [PMID: 34831100 DOI: 10.3390/cells10112877] [Reference Citation Analysis]
8 Hofstetter G, Grech C, Pils D, Pammer J, Neudert B, Pötsch N, Baltzer P, Traub-weidinger T, Seebacher V, Aust S. Prostate-Specific Membrane Antigen (PSMA) Expression in Tumor-Associated Neovasculature Is an Independent Prognostic Marker in Patients with Ovarian Cancer. JPM 2022;12:551. [DOI: 10.3390/jpm12040551] [Reference Citation Analysis]
9 Klein Nulent TJW, van Es RJJ, Willems SM, Braat AJAT, Devriese LA, de Bree R, de Keizer B. First experiences with 177Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer. EJNMMI Res 2021;11:126. [PMID: 34905121 DOI: 10.1186/s13550-021-00866-8] [Reference Citation Analysis]
10 Filippi L, Schillaci O. Total-body [18F]FDG PET/CT scan has stepped into the arena: the faster, the better. Is it always true? Eur J Nucl Med Mol Imaging 2022. [PMID: 35396968 DOI: 10.1007/s00259-022-05791-z] [Reference Citation Analysis]
11 Vit O, Patel M, Musil Z, Hartmann I, Frysak Z, Miettinen M, Pacak K, Petrak J. Deep Membrane Proteome Profiling Reveals Overexpression of Prostate-Specific Membrane Antigen (PSMA) in High-Risk Human Paraganglioma and Pheochromocytoma, Suggesting New Theranostic Opportunity. Molecules 2021;26:6567. [PMID: 34770976 DOI: 10.3390/molecules26216567] [Reference Citation Analysis]
12 Wen J, Zhu Y, Li L, Liu J, Chen Y, Chen R. Determination of optimal 68 Ga-PSMA PET/CT imaging time in prostate cancers by total-body dynamic PET/CT. Eur J Nucl Med Mol Imaging 2021. [PMID: 34962583 DOI: 10.1007/s00259-021-05659-8] [Reference Citation Analysis]
13 Privé BM, Derks YHW, Rosar F, Franssen GM, Peters SMB, Khreish F, Bartholomä M, Maus S, Gotthardt M, Laverman P, Konijnenberg MW, Ezziddin S, Nagarajah J, Heskamp S. 89Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-I&T: a preclinical evaluation and first in man. Eur J Nucl Med Mol Imaging 2021. [PMID: 34932154 DOI: 10.1007/s00259-021-05661-0] [Reference Citation Analysis]
14 Uijen MJM, Weijers JAM, Driessen CML, van Herpen CML, Nagarajah J. 68Ga-Prostate-Specific Membrane Antigen-Avid Malignant Pleural Effusion in a Patient With Metastatic Adenoid Cystic Carcinoma and Concordance With 18F-FDG PET/CT. Clin Nucl Med 2022;47:140-1. [PMID: 35006109 DOI: 10.1097/RLU.0000000000004015] [Reference Citation Analysis]